Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

How Melanogenesis Changes With Age

Melanogenesis is the enzymatic pathway that produces melanin; age-related change in this pathway is documented as a decline in melanocyte density and a shift in the distribution of pigment, with much of the mechanistic w

peptides-pro Editorial

Melanogenesis is the biosynthetic pathway by which melanin pigment is produced, and its rate-limiting step is catalysed by the copper-dependent enzyme tyrosinase [2]. Age-related change in this pathway is not a single event: the literature describes a decline in the number of functioning melanocytes in some regions alongside focal increases in pigment production in others, so that the same skin can show both hypopigmented and hyperpigmented areas. The formal identifiers of the pathway's central enzyme are not given in the evidence assembled here; what the evidence does establish is that tyrosinase catalyses the rate-limiting step of melanogenesis and that it is treated as a principal molecular target in pigmentation research [1][2].

The work centres on the tyrosinase enzyme and on the transcription factor microphthalmia-associated transcription factor (MITF), together with the melanocortin receptors, which regulate pigmentation as part of a broader set of molecular targets in skin biology [1].

Research Studies

Tyrosinase and the rate-limiting step of melanogenesis

Tyrosinase is described as the key enzyme catalysing the rate-limiting step in melanogenesis, which is why it is the most frequently targeted node in pigment research [2]. A recurring methodological problem is stated plainly in the evidence: many inhibitors identified against mushroom-derived tyrosinase show limited efficacy against the human enzyme, so findings from mushroom enzyme assays do not transfer directly to human tyrosinase [2].

Aminonaphthoquinone-chalcone hybrids and human tyrosinase in silico

An in silico study evaluated aminonaphthoquinone-chalcone hybrids against human tyrosinase using molecular docking. All ten hybrids showed higher binding affinity than kojic acid, and six of them (compounds 3, 4, 5, 7, 9 and 10) showed higher binding affinity than the remainder and interacted with amino acid residues within the tyrosinase active site [2]. These are computational predictions, not measurements in cells or tissue.

N-(2-mercaptoethyl)benzamide derivatives in mushroom enzyme and B16F10 cells

N-(2-mercaptoethyl)benzamide (NMEB) derivatives 1a–1m were designed as Cu(II) chelators and assessed for tyrosinase inhibition. Derivative 1m inhibited mushroom tyrosinase activity twice as potently as kojic acid in the presence of l-DOPA, and kinetic studies characterised the inhibition mechanism for three derivatives including 1m. All NMEB derivatives suppressed melanogenesis more potently than kojic acid in B16F10 cells, reducing melanin production in a concentration-dependent manner [3]. B16F10 is a murine melanoma cell line, so this is cell-culture evidence, not human data.

4-(4-fluorobenzyl)piperazine-acetanilide conjugates in enzymatic assays

A series of 4-(4-fluorobenzyl)piperazine derivatives (2a–u) was designed, synthesised and evaluated as tyrosinase inhibitors. In in vitro enzymatic assays using l-DOPA as substrate, several derivatives showed higher inhibitory activity than kojic acid under identical experimental conditions [5].

Cannabidiol-thiosemicarbazone in human skin-derived cells

CBD-TSC1, a cannabidiol-based thiosemicarbazone derivative, was investigated as a modulator of melanogenesis in human skin-derived cells, with the stated rationale that existing tyrosinase inhibitors are often limited by low potency, instability or cytotoxicity [8]. This is a human cell-derived model rather than a clinical study.

Coreopsis tinctoria and multi-target enzyme inhibition

Coreopsis tinctoria Nutt., known as Kunlun snow chrysanthemum, was examined through an ethnopharmacology-guided ligand-fishing approach for multi-target enzyme inhibition, including tyrosinase [7]. The plant is described as a traditional medicinal and edible species of the high-altitude regions of Xinjiang, China [7].

Melasma as a refractory pigmentation disorder and its microenvironment

Clinically refractory melasma is described as difficult to treat because it is driven by a multidimensional pathological microenvironment comprising melanocyte hyperactivity, aberrant vascular growth, oxidative stress and chronic inflammation; single-pathway therapies therefore often produce incomplete or transient responses [6]. This framing matters for age-related pigment change because it indicates that pigmentation outcomes are not governed by tyrosinase activity alone.

Laser and oral tranexamic acid in melasma: a clinical observation

A registered clinical observation examined 1064-nm Q-switched fractional laser combined with oral tranexamic acid for melasma. Melasma is characterised in the record as a common acquired condition of symmetric hyperpigmentation, typically on the face, with higher prevalence in females and in darker skin types. The 1064-nm Q-switched wavelength is absorbed by pigment, leading to damage of pigment and melanocyte; earlier protocols using this wavelength required large spot sizes and repeated low-energy scanning, with a terminal reaction of redness and a lesion temperature rise of about 2 °C [4].

Model or systemWhat was measuredComparator
Human tyrosinase, in silico dockingBinding affinity of 10 aminonaphthoquinone-chalcone hybridsAll 10 higher than kojic acid; 6 highest of the set [2]
Mushroom tyrosinase, l-DOPA substrateInhibition by NMEB derivative 1mTwice as potent as kojic acid [3]
B16F10 murine melanoma cellsMelanin production with NMEB derivativesMore potent suppression than kojic acid, concentration-dependent [3]
Enzymatic assay, l-DOPA substrateInhibition by 4-(4-fluorobenzyl)piperazine derivatives 2a–uSeveral higher than kojic acid under identical conditions [5]

Where the evidence is animal-only or in vitro

The mechanistic claims above rest on in silico docking, purified mushroom enzyme assays, a murine melanoma cell line, and human skin-derived cells in culture [2][3][5][8]. None of these establishes an effect in a living human. The clinical material in the evidence concerns melasma treatment by laser and oral tranexamic acid, not the age-related trajectory of melanogenesis itself [4].

If you are reading this for personal health reasons

The materials described here are supplied for laboratory research use only, and we do not provide dosing information or medical guidance of any kind. Anyone considering a compound for their own use should speak to a licensed clinician.

Sources

WhatsApp